Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Full description

Bibliographic Details
Main Authors: Marianne Berdugo, Kimberley Delaunay, Cécile Lebon, Marie-Christine Naud, Lolita Radet, Léa Zennaro, Emilie Picard, Alejandra Daruich, Jacques Beltrand, Elsa Kermorvant-Duchemin, Michel Polak, Patricia Crisanti, Francine F. Behar-Cohen
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceutics
Subjects:
diabetic retinopathy
retinal neuroprotection
glibenclamide
glyburide
sulfonylureas
diabetes complications
Online Access:https://www.mdpi.com/1999-4923/13/7/1095

Internet

https://www.mdpi.com/1999-4923/13/7/1095

Similar Items